Foresee Pharmaceuticals Co., Ltd. (6576) AI Stock Analysis

Foresee Pharmaceuticals Co., Ltd.

(TPEx:6576)

Select Model

Rating:42Neutral

Price Target:TWD 69.00▼(-5.61% Downside)

Action:initiatedcoverage

Date:11/10/26

Weak financial performance driven by persistent losses and cash burn is the primary drag, followed by bearish technical signals from price action and MACD. Stretched valuation metrics further constrain the score.

Positive Factors

Long-acting injectable platformThe sustained-release platform targets more convenient dosing and improved adherence, giving Foresee a defined specialty focus rather than a broad, undifferentiated drug portfolio. If product development and commercialization continue successfully, this technology base can support repeatable applications across relevant therapeutic areas.

Negative Factors

Persistent cash burnRepeatedly negative operating and free cash flow means the company is not currently self-funding its operations or development activities. Continued cash consumption raises the need for external financing, which can restrict strategic flexibility and create recurring dilution or funding pressure over the next several quarters.

Foresee Pharmaceuticals Co., Ltd. (6576) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 11.42B
Dividend Yield: ―
Average Volume (3M): 121.58K
Price to Earnings (P/E): 524.3
Beta (1Y): 0.41
Revenue Growth: 6.41%
EPS Growth: ―
Country: TW
Employees: 1,760
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Foresee Pharmaceuticals Co., Ltd. Business Overview & Revenue Model

Company Description

Foresee is a Taiwan and US-based biopharmaceutical company focused on two key areas: its unique Stabilized Injectable Formulation (SIF) long-acting injectable technology with derived drug products for specialty markets, and its transformative preclin...

Foresee Pharmaceuticals Co., Ltd. Financial Statement Overview

Summary

Revenue rebound and low debt-to-equity ratio of 0.25 provide some stability, but large net losses, negative margins around -205%, and heavy cash burn of -858 million create significant sustainability risks.

Income Statement

32Negative

Balance Sheet

58Neutral

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	471.13M	431.27M	418.69M	195.04M	301.51M	226.03M
Gross Profit	104.12M	294.22M	239.80M	113.97M	275.97M	175.08M
EBITDA	-435.22M	-784.50M	-945.98M	-912.16M	-386.58M	-475.83M
Net Income	22.50M	-883.15M	-1.08B	-1.04B	-472.64M	-569.27M
Balance Sheet
Total Assets	1.86B	1.31B	2.16B	1.86B	1.30B	1.64B
Cash, Cash Equivalents and Short-Term Investments	910.92M	700.22M	1.44B	1.35B	689.50M	1.27B
Total Debt	398.33M	231.74M	260.32M	228.26M	41.32M	16.65M
Total Liabilities	585.57M	380.78M	560.15M	616.93M	393.43M	321.26M
Stockholders Equity	1.27B	929.61M	1.60B	1.24B	910.58M	1.32B
Cash Flow
Free Cash Flow	-599.86M	-857.73M	-1.33B	-933.84M	-291.29M	-220.98M
Operating Cash Flow	-545.15M	-842.23M	-1.17B	-887.55M	-233.22M	-213.33M
Investing Cash Flow	183.01M	-161.75M	112.82M	-296.08M	40.70M	17.62M
Financing Cash Flow	348.23M	134.18M	1.41B	1.50B	2.86M	-75.74M

Foresee Pharmaceuticals Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6576 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:1720	71Outperform	TWD 10.81B	10.22	―	3.64%	4.62%	9.56%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6576	42Neutral	TWD 11.52B	524.28	―	―	6.41%	―
TW:6617	40Underperform	TWD 15.11B	-89.26	―	―	11.66%	-72.43%
TW:6945	40Underperform	TWD 11.22B	-20.83	―	―	―	―
TW:6535	39Underperform	TWD 12.33B	-31.94	―	―	-24.84%	9.15%

* General Sector Average

Performance Comparison

TW:6576 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6576	Foresee Pharmaceuticals Co., Ltd.	73.10	-4.40	-5.68%
TW:1720	Standard Chemical & Pharmaceutical Co. Ltd.	55.00	2.61	4.99%
TW:6467	TAHO Pharmaceuticals Ltd	246.00	70.00	39.77%
TW:6535	LUMOSA THERAPEUTICS CO LTD	73.50	-116.50	-61.32%
TW:6617	Gongwin Biopharm Holdings Co., Ltd.	118.50	32.10	37.15%
TW:6945	AP Biosciences, Inc.	115.00	1.00	0.88%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Foresee Pharmaceuticals Co., Ltd. AI Stock Analysis